肺癌患者静脉血栓栓塞危险因素的研究进展

doi:10.3969/j.issn.1004-583X.2025.05.017

摘要/Abstract

摘要：

肺癌是全球发病率及死亡率均最高的恶性肿瘤,也是一种与血栓形成事件密切相关的恶性肿瘤。静脉血栓栓塞主要包括深静脉血栓形成和肺栓塞,其中最危险的是肺栓塞。肺栓塞时患者会出现呼吸困难、胸痛和(或)咯血、肺动脉压力升高甚至死亡,严重影响患者的生活质量和预后。本文对肺癌患者发生静脉血栓栓塞的危险因素进行综述,旨在为构建出适合肺癌患者的血栓预测模型提供理论依据。

中图分类号:

R734.2

田晓婷, 卢泽芬. 肺癌患者静脉血栓栓塞危险因素的研究进展[J]. 临床荟萃, 2025, 40(5): 473-476.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2025.05.017

https://lchc.magtechjournal.com/CN/Y2025/V40/I5/473

参考文献 41

[1]	王培宇, 黄祺, 王少东, 等. 《全球癌症统计数据2022》要点解读[J]. 中国胸心血管外科临床杂志, 2024, 31(7):933-954.
[2]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231.
[3]	Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: A population-based cohort study[J]. Blood, 2021, 137(14):1959-1969. doi: 10.1182/blood.2020007338 pmid: 33171494
[4]	Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(10):1181-1201.
[5]	Xu Y, Wu T, Ren X, et al. Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: A systematic review and meta-analysis[J]. Front Oncol, 2024, 14:1405147.
[6]	Weitz JI, Haas S, Ageno W, et al. Cancer associated thrombosis in everyday practice: Perspectives from GARFIELD-VTE[J]. J Thromb Thrombolysis, 2020, 50(2):267-277.
[7]	Lyman GH, Culakova E, Poniewierski MS, et al. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer[J]. Thromb Res, 2018, 164 Suppl 1:S112-S118.
[8]	Howlett J, Benzenine E, Cottenet J, et al. Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study[J]. BMC Cancer, 2020, 20(1):461. doi: 10.1186/s12885-020-06930-1 pmid: 32448219
[9]	Khorana AA, Kuderer NM, McCrae K, et al. Healthcare costs of patients with cancer stratified by Khorana score risk levels[J]. J Med Econ, 2021, 24(1):866-873.
[10]	Takemoto T, Soh J, Ohara S, et al. The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery[J]. Surg Today, 2021, 51(9):1480-1487. doi: 10.1007/s00595-021-02243-3 pmid: 33611651
[11]	Pastori D, Cormaci VM, Marucci S, et al. A comprehensive review of risk factors for venous thromboembolism: From epidemiology to pathophysiology[J]. Int J Mol Sci, 2023, 24(4):3169.
[12]	Yan AR, Samarawickrema I, Naunton M, et al. Risk factors and prediction models for venous thromboembolism in ambulatory patients with lung cancer[J]. Healthcare (Basel), 2021, 9(6):778.
[13]	Pabinger I, Ay C, Dunkler D, et al. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the vienna cancer and thrombosis study (CATS)[J]. J Thromb Haemost, 2015, 13(1):17-22. doi: 10.1111/jth.12778 pmid: 25381723
[14]	Mahajan A, Brunson A, Adesina O, et al. The incidence of cancer-associated thrombosis is increasing over time[J]. Blood Adv, 2022, 6(1):307-320.
[15]	Ohashi Y, Ikeda M, Kunitoh H, et al. Corrigendum to: Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry[J]. Jpn J Clin Oncol, 2020, 50(11):1346. doi: 10.1093/jjco/hyaa160 pmid: 32778867
[16]	李甜甜, 石莉程, 孔辉, 等. 肺腺癌并发静脉血栓栓塞症的危险因素及其预测效能[J]. 山东医药, 2021, 61(18):84-87.
[17]	Zhu VW, Zhao JJ, Gao Y, et al. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis[J]. Lung Cancer, 2021, 157:147-155. doi: 10.1016/j.lungcan.2021.05.019 pmid: 34049720
[18]	Al-Samkari H, Leiva O, Dagogo-Jack I, et al. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC[J]. J Thorac Oncol, 2020, 15(9):1497-1506. doi: S1556-0864(20)30380-4 pmid: 32437899
[19]	Ala-Seppälä HM, Ukkonen MT, Laurikka JO, et al. The early and long-term occurrence of symptomatic venous thromboembolism after lung cancer surgery without extended thromboprophylaxis-a single center experience with 435 patients[J]. J Thorac Dis, 2024, 16(7):4329-4339. doi: 10.21037/jtd-24-308 pmid: 39144340
[20]	杜晖, 赵洪林, 赵青春, 等. 肺癌术后患者下肢深静脉血栓的发生率及相关危险因素分析[J]. 中国肺癌杂志, 2023, 26(5):386-391.
[21]	Huang H, Korn JR, Mallick R, et al. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: A retrospective database study[J]. J Thromb Thrombolysis, 2012, 34(4):446-456.
[22]	Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment[J]. Cancers (Basel), 2018, 10(10):380.
[23]	Mitani A, Jo T, Yasunaga H, et al. Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy[J]. Anticancer Drugs, 2018, 29(6):560-564. doi: 10.1097/CAD.0000000000000625 pmid: 29570101
[24]	Grover SP, Hisada YM, Kasthuri RS, et al. Cancer therapy-associated thrombosis[J]. Arterioscler Thromb Vasc Biol, 2021, 41(4):1291-1305. doi: 10.1161/ATVBAHA.120.314378 pmid: 33567864
[25]	Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the arbeitsgemeinschaft internistische onkologie[J]. J Clin Oncol, 2008, 26(9):1435-1442.
[26]	Chen N, Ren M, Li R, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma[J]. Mol Cancer, 2015, 14:140. doi: 10.1186/s12943-015-0418-x pmid: 26215730
[27]	Lorenzi M, Ferro A, Cecere F, et al. First-line osimertinib in patients with EGFR-Mutant advanced non-small cell lung cancer: Outcome and Safety in the real world: FLOWER study[J]. Oncologist, 2022, 27(2):87-e115.
[28]	Regev A, Avigan MI, Kiazand A, et al. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development[J]. J Autoimmun, 2020, 114:102514.
[29]	Alghamdi EA, Aljohani H, Alghamdi W, et al. Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports[J]. Saudi Pharm J, 2022, 30(8):1193-1199. doi: 10.1016/j.jsps.2022.06.010 pmid: 36164566
[30]	Byrne M, Reynolds JV, O'Donnell JS, et al. Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery[J]. Br J Cancer, 2010, 102(1):73-79.
[31]	Temraz S, Moukalled N, Gerotziafas GT, et al. Association between radiotherapy and risk of cancer associated venous thromboembolism: A sub-analysis of the COMPASS-CAT study[J]. Cancers (Basel), 2021, 13(5):1033.
[32]	董鲜桃, 张永杰, 朱姝, 等. 肺癌化疗患者经外周静脉穿刺的中心静脉导管置管后发生上肢深静脉血栓的危险因素及其风险预测列线图模型构建[J]. 实用心脑肺血管病杂志, 2022, 30(8):8-12.
[33]	Moik F, Chan WE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy[J]. Blood, 2021, 137(12):1669-1678. doi: 10.1182/blood.2020007878 pmid: 33067632
[34]	Herre M, Cedervall J, Mackman N, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembol neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases[J]. Physiol Rev, 2023, 103(1):277-312.
[35]	LEVIN J, CONLEY CL. THROMBOCYTOSIS ASSOCIATED WITH MALIGNANT DISEASE[J]. Arch Intern Med, 1964, 114:497-500. pmid: 14184638
[36]	Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis[J]. Hamostaseologie, 2014, 34(1):54-62. doi: 10.5482/HAMO-13-10-0054 pmid: 24305775
[37]	Anghel L, Sascău R, Radu R, et al. From classical laboratory parameters to novel biomarkers for the diagnosis of venous thrombosis[J]. Int J Mol Sci, 2020, 21(6):1920.
[38]	Hisada Y, Garratt KB, Maqsood A, et al. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer[J]. Blood Adv, 2021, 5(2):487-495. doi: 10.1182/bloodadvances.2020003149 pmid: 33496742
[39]	Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1[J]. Blood, 2010, 116(1):113-121. doi: 10.1182/blood-2010-02-267740 pmid: 20385790
[40]	Gogia S, Neelamegham S. Role of fluid shear stress in regulating VWF structure, function and related blood disorders[J]. Biorheology, 2015, 52(5-6):319-335. doi: 10.3233/BIR-15061 pmid: 26600266
[41]	Hisada Y, Mackman N. Mechanisms of cancer-associated thrombosis[J]. Res Pract Thromb Haemost, 2023, 7(3):100123.

肺癌患者静脉血栓栓塞危险因素的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	肇雪婷, 白佳雯, 孙军. 代谢相关脂肪性肝病肝纤维化危险因素分析及构建预测模型[J]. 临床荟萃, 2025, 40(5): 417-422.
[2]	肖珂, 王奇. 2型糖尿病伴隐球菌性脑膜炎患者的临床特征及危险因素分析[J]. 临床荟萃, 2025, 40(5): 423-427.
[3]	许慧峰, 晋艳勇, 苟若澜, 胡明哲. 脑出血患儿并发脑积水的危险因素及预测模型[J]. 临床荟萃, 2025, 40(4): 325-328.
[4]	童明霞, 陈柯, 向小聪, 周丽峰. 中青年体检人群瘦型代谢相关脂肪性肝病及其危险因素分析[J]. 临床荟萃, 2025, 40(2): 128-132.
[5]	钱晨莹, 闫文君, 黄燕, 赵志. 肝硬化失代偿期患者合并多重耐药菌感染的危险因素分析[J]. 临床荟萃, 2025, 40(2): 143-146.
[6]	蒲茜, 成刚, 道杰草, 齐梓兆, 窦乐乐, 赵军芳, 张文君, 郭彩霞, 王莹莹. 甘肃地区单中心慢性肾脏病患者便秘患病率及危险因素分析[J]. 临床荟萃, 2025, 40(1): 44-53.
[7]	赵一品, 崔清洋. 超早产儿/超低出生体重儿支气管肺发育不良危险因素分析[J]. 临床荟萃, 2025, 40(1): 60-64.
[8]	韩铠阳, 冯铜铜, 包瑛. 儿童狼疮性肾炎合并神经精神狼疮的临床特征和危险因素[J]. 临床荟萃, 2024, 39(9): 812-815.
[9]	高胜男, 张冉冉, 张羽曦, 高宁, 冯冰, 刘国强. 我国糖尿病神经病理性疼痛疾病负担及药物治疗进展[J]. 临床荟萃, 2024, 39(9): 842-846.
[10]	焦菲, 姚治平, 王兰桂. 中枢神经系统棘球幼病(包虫病)癫痫发作的危险因素[J]. 临床荟萃, 2024, 39(8): 712-715.
[11]	王娇燕, 严超, 应可净. 气道慢性炎症性疾病并发静脉血栓栓塞症的研究进展[J]. 临床荟萃, 2024, 39(5): 470-474.
[12]	陈诗雨, 罗专波. 肿瘤相关静脉血栓栓塞症研究进展[J]. 临床荟萃, 2024, 39(4): 363-369.
[13]	李倩, 钟平. 帕金森病伴脑白质病变患者临床特征及危险因素分析[J]. 临床荟萃, 2024, 39(3): 222-226.
[14]	李瑞珍, 李星辉, 曾璟, 张小明, 张惠娟, 尹龙, 张展, 昂文成林龙珠. 急性心肌梗死合并心脏破裂的研究进展[J]. 临床荟萃, 2024, 39(3): 264-268.
[15]	贺田, 韩琳秋, 施祖新, 沈鸣雁. 肝移植患者术后多重耐药菌感染发生率及危险因素的meta分析[J]. 临床荟萃, 2024, 39(11): 965-973.